Study Population (n = 123) | AHR Positive (n = 81) | AHR Negative (n = 42) |
p-value
|
|
Demographic data | ||||
Male sex | 64 (52.0) | 42 (51.9) | 22 (52.4) | 0.96 |
Age at time of diagnosis, years | 10.5 (8.0-13.0) | 9.7 (7.1-12.0) | 12.3 (9.7-14.0) | 0.001 |
Family history of allergic disease | 38 (30.9) | 24 (29.6) | 14 (33.3) | 0.67 |
Family history of asthma | 18 (14.6) | 12 (14.8) | 6 (14.3) | 0.94 |
Family history of hay fever | 25 (20.3) | 13 (16.0) | 12 (28.6) | 0.10 |
Family history of eczema | 6 (4.9) | 4 (4.9) | 2 (4.8) | 0.97 |
Co-existence of 2 or more atopic diseases in family | 10 (8.1) | 4 (4.9) | 6 (14.3) | 0.07 |
Aeroallergen sensitization | 62 (50.0) | 47 (58.0) | 15 (35.7) | 0.019 |
-Tree pollen | 35 (28.5) | 30 (37.0) | 5 (11.9) | 0.003 |
-Grass pollen | 48 (39.0) | 36 (44.4) | 12 (28.6) | 0.09 |
-Animal dander | 26 (21.1) | 22 (27.2) | 4 (9.5) | 0.023 |
-Mold | 7 (5.7) | 5 (6.2) | 2 (4.8) | 0.75 |
-House dust mite | 45 (36.6) | 36 (44.4) | 9 (21.4) | 0.012 |
Accompanying eczema | 25 (20.3) | 17 (21.0) | 8 (19.0) | 0.80 |
Accompanying allergic rhinitis/conjuntivitis | 38 (30.9) | 27 (33.3) | 11 (26.2) | 0.42 |
Pet ownership | 51 (41.5) | 36 (44.4) | 15 (35.7) | 0.35 |
Smoke exposition at home | 13 (10.6) | 10 (12.3) | 3 (7.1) | 0.37 |
Admission symptoms | ||||
Daytime cough | 67 (54.5) | 49 (60.5) | 18 (42.9) | 0.06 |
Nocturnal cough | 29 (23.6) | 25 (30.9) | 4 (9.5) | 0.008 |
Exercise-induced cough | 30 (24.4) | 23 (28.4) | 7 (16.7) | 0.15 |
Co-existence of nocturnal and exercise-induced cough | 12 (9.8) | 11 (13.6) | 1 (2.4) | 0.047 |
Dyspnea | 39 (31.7) | 28 (34.6) | 11 (26.2) | 0.34 |
Exercise-induced dyspnea | 60 (48.8) | 36 (44.4) | 24 (57.1) | 0.18 |
Daytime cough and/or dyspnea | 84 (68.3) | 60 (74.1) | 24 (57.1) | 0.06 |
Exercise-induced cough and/or exercise-induced dyspnea | 78 (63.4) | 50 (61.7) | 28 (66.7) | 0.59 |
Ever wheezing | 71 (57.7) | 54 (66.7) | 17 (40.5) | 0.005 |
Wheezing not associated to colds | 20 (16.3) | 18 (22.2) | 2 (4.8) | 0.013 |
Wheezing associated to colds | 62 (50.4) | 47 (58.0) | 15 (35.7) | 0.019 |
Laboratory parameters a | ||||
Peripheral blood eosinophilia count > 500/µL | 19 (15.4) | 18 (22.2) | 1 (2.4) | 0.002 |
Peripheral blood eosinophilia | 4.0 (2.5-7.0) | 5.6 (2.8-8.9) | 2.8 (2.2-4.2) | 0.004 |
Serum total IgE | 123 (30-355) | 150 (36-489) | 77 (18-295) | 0.07 |
Spirometry parameters | ||||
Baseline FEV1, % | 100 (90-109) | 100 (90-109) | 101 (92-111) | 0.49 |
Baseline FVC, % | 93 (85-105) | 93 (82-105) | 93 (85-105) | 0.84 |
Baseline FEV1/FVC ratio, % | 100 (89-112) | 100 (89-111) | 102 (89-117) | 0.56 |
Baseline FEF25, % | 87 (77-98) | 87 (77-95) | 89 (75-99) | 0.70 |
Baseline FEF50, % | 84 (75-98) | 83 (74-97) | 89 (80-104) | 0.13 |
Baseline FEF75, % | 78 (64-103) | 77 (61-99) | 86 (69-110) | 0.08 |
Baseline FEF25 <65% | 13 (10.6) | 7 (8.6) | 6 (14.3) | 0.33 |
Baseline FEF50 <65% | 12 (9.8) | 10 (12.3) | 2 (4.8) | 0.18 |
Baseline FEF75 <65% | 31 (25.2) | 25 (30.9) | 6 (14.3) | 0.045 |
Data are presented as count (%) or median (interquartile range). Abbreviations: AHR, airway hyperresponsiveness; IgE, immunoglobulin E; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEFxx, forced expiratory flow at XX percent of vital capacity. a Laboratory parameters were available in the study population (AHR+/AHR-) only from 80 (52/28), 93 (61/32), and 95 (62/33) children for peripheral blood eosinophilia count>500/μL), peripheral blood eosinophilia % and serum total IgE, respectively. | Data are presented as count (%) or median (interquartile range). Abbreviations: AHR, airway hyperresponsiveness; IgE, immunoglobulin E; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEFxx, forced expiratory flow at XX percent of vital capacity. a Laboratory parameters were available in the study population (AHR+/AHR-) only from 80 (52/28), 93 (61/32), and 95 (62/33) children for peripheral blood eosinophilia count>500/μL), peripheral blood eosinophilia % and serum total IgE, respectively. | Data are presented as count (%) or median (interquartile range). Abbreviations: AHR, airway hyperresponsiveness; IgE, immunoglobulin E; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEFxx, forced expiratory flow at XX percent of vital capacity. a Laboratory parameters were available in the study population (AHR+/AHR-) only from 80 (52/28), 93 (61/32), and 95 (62/33) children for peripheral blood eosinophilia count>500/μL), peripheral blood eosinophilia % and serum total IgE, respectively. | Data are presented as count (%) or median (interquartile range). Abbreviations: AHR, airway hyperresponsiveness; IgE, immunoglobulin E; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEFxx, forced expiratory flow at XX percent of vital capacity. a Laboratory parameters were available in the study population (AHR+/AHR-) only from 80 (52/28), 93 (61/32), and 95 (62/33) children for peripheral blood eosinophilia count>500/μL), peripheral blood eosinophilia % and serum total IgE, respectively. | Data are presented as count (%) or median (interquartile range). Abbreviations: AHR, airway hyperresponsiveness; IgE, immunoglobulin E; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEFxx, forced expiratory flow at XX percent of vital capacity. a Laboratory parameters were available in the study population (AHR+/AHR-) only from 80 (52/28), 93 (61/32), and 95 (62/33) children for peripheral blood eosinophilia count>500/μL), peripheral blood eosinophilia % and serum total IgE, respectively. |